Botulinum toxin (BT)is a kind of bacterial exotoxin produced during the proliferation of Clostridium botulinum, which is classified as a neurotoxin. Based on its antigencity, BT is divided into 7 subtypes, including A, B, C, D, E, F and G. B'T type A has been widely used in clinical treatment, becoming the preferred treatment for focal spasm and dystonia. BT type A has been approved for marketing in China including onabotulinumtoxin A (ONA)and BTX-A. With the increasingly wide spread clinical application of ONA and BTX-A in China, the difference in therapeutic eficacy between ONA and BTX-A has attracted moreand more attention. Based on this, a comparison has been conducted to assess the difference in clinical effcacy to provide guidance for clinical practice.